Abivax receives Phase IIb trial authorisation from Canada for ABX464
Global Roundup: Abivax Eyes Phase III Following Positive UC Data | BioSpace
HIV pipeline 2017: full version | HTB | HIV i-Base
Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124
Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464 – lncRNA Blog
Abivax: A Biotech With Blockbuster Potential (OTCMKTS:AAVXF) | Seeking Alpha
Abivax to evaluate anti-inflammatory effects of ABX464 in large-scale COVID-19 trial – Truffle
Abivax 2018 Financial Results and Operations Update | Business Wire
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect
ABX464 enticing for Covid-19; mechanism, trial issues belie potential
Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases: Trends in Molecular Medicine
ABX464's Clinical Benefits for Inflammatory Diseases Revealed in Review
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis | Retrovirology | Full Text
Abivax (@Abivax_) / Twitter
Abivax: Most Ideal Big Pharma M&A Target In 2022 (AAVXF) | Seeking Alpha
Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv
We develop one of the World's Most Advanced Functional HIV Cure”
ABIVAX's ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial | World Pharma Today
Mechanism of action of anti-HIV drug, ABX464, published
Abivax | LinkedIn
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect
Abivax First-Half 2018 Financial Results and Operations Update | Abivax
Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv
Abivax reports excellent efficacy and safety of ABX464 in Phase IIb
